Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape

IMPACT Medicom
04/09/2024 17 min
Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape

Listen "Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape"

Descargar episodio

Episode Synopsis

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest:Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.comThis episode was funded by Eli Lilly, Canada. 

More episodes of the podcast IMPACT Medicom

Thoracic Surgery Series: Resection after Neoadjuvant Immunotherapy 10/11/2025
Highlights from EHA/ICML 2025: International Perspective on CLL 26/06/2025
Prise en charge de la PN associée au BV utilisé pour le traitement de première intention du cH 27/03/2025
Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in cHL 26/03/2025
ASH 2024: Updates on CLL 29/12/2024
Highlights from EHA 2024 - Updates on the Treatment of CLL 02/07/2024
LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL 21/06/2024
Cutting Edge Advances in the Treatment of Lung Cancer 19/04/2024
Precision Medicine Series: Ep15: Biomarkers in Upper GI Cancers 18/04/2024
Management of Cutaneous Squamous Cell Carcinoma (cSCC): A Surgeon’s Perspective 25/03/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA